Current lymphoma treatment methods include radiotherapy, chemotherapy, hematopoietic stem cell transplantation and antibody immunotherapy. However, some patients still do not respond to treatment or relapse rapidly after treatment, with rapid disease progression and poor prognosis. In recent years, research on immunotherapy of lymphoma with dendritic cell (DC) vaccine has received extensive attention. By immunizing lymphoma patients with DCs carrying tumor antigens, specific and long-lasting anti-tumor immune responses can be induced. The clinical application of DC vaccine was first reported by Hsu et al. in Nature Medicine in 1996, in which four patients with follicular lymphoma who had failed conventional chemotherapy were treated with Id antigen-impacted mature DCs, and all four patients produced anti-tumor immune responses after immunization, including one patient who achieved molecular remission, one patient who achieved complete remission (CR), and one patient who achieved partial remission (CR). (CR), 1 partial remission (PR), and 1 ineffective, and no significant toxic side effects were observed, which made people confident in the application of DC immunotherapy for malignant tumors. Since then, Timmerman et al. from Stanford University conducted further clinical trials and reported 35 patients (25 in initial remission after chemotherapy) treated with DC and Id-KLH. The patients were all stage III and IV follicular lymphoma with peripheral lymph nodes >2 × 2 cm. Results: T-cell proliferative responses against Id were detected in 8 of the first 10 patients, and 4 produced clinical responses, including 2 CRs with disease progression-free time (PF) of 44 -57 months after immunization; 1 PR with PF of 12 months; and 1 molecular biological remission with PF of 75 months. Hus et al. reported 9 patients with CLL/SLL who received DC induced by allogeneic monocytes shocked with lymphoma cell lysates or apoptotic vesicles, and observed enhanced T-cell responses against RHAMM peptides and decreased peripheral blood lymphocytes in 4 patients and stable disease for more than 2 years in 5 patients. There are fewer effective therapeutic measures for cutaneous T-cell lymphoma (CTCL). Maier et al. reported that in 10 patients with CTCL who received weekly intra-lymph node injections of DC tumor seedling cells, a tumor-specific delayed allergic reaction (DTH) response was detected in 8 patients, 5 of the 10 patients had a significant response, 1 patient had a CR for >19 months, 4 PRs, 2 of which had sustained PR The mean PR period was 10.5 months in the other 2 cases. Conclusion We pioneered the work of DC immunotherapy for lymphoma in China in 2004 and established a standardized treatment system, which provides a new treatment strategy for relapsed and refractory lymphoma. In a patient with diffuse large B-cell lymphoma, after repeated combined chemotherapy and melphalan treatment failed, some lymphoma tissues were taken to prepare freeze-thaw antigen impacted DC prepared as a therapeutic vaccine, and the patient was immunized with combined CIK, and significant lymphoma regression and tumor volume reduction >50% was observed after 14 days